Refer refractory afib for catheter ablation

In this unblinded trial, 167 patients with recurrent symptomatic afib despite anti-arrythmic therapy were randomized to catheter ablation or another anti-arrythmic therapy. At 9 months, 66% of the catheter group remained free of recurrent afib, compared to only 16% of the anti-arrythmic group. Treatment related major adverse effects occurred in 5% of the catheter group compared to 9% of the anti-arrythmic group at 30 days. Catheter ablation is a reasonable treatment strategy for patients with symptomatic paroxysmal afib refractory to medical therapy (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment